Brief: Exelixis Presents Final Overall Survival Results From Phase 3 Contact-02 Pivotal Study

Exelixis

15/09/2024 13:56

Sept 15 (Reuters) - Exelixis Inc  EXEL.O :
    * EXELIXIS PRESENTS FINAL OVERALL SURVIVAL RESULTS FROM
PHASE 3
CONTACT-02 PIVOTAL STUDY EVALUATING CABOZANTINIB IN COMBINATION
WITH AN IMMUNE CHECKPOINT INHIBITOR IN METASTATIC
CASTRATION-RESISTANT PROSTATE CANCER AT ESMO 2024
    * EXELIXIS INC - PHASE 3 CONTACT-02 TRIALS SHOW NUMERICAL
BUT NOT
SIGNIFICANT OS IMPROVEMENT

Source text for Eikon:  ID:nBw2Vjj3na 
Further company coverage:  EXEL.O 

 ((Reuters.Briefs@thomsonreuters.com;))